Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Call Participants Josh Jennings - TD Cowen Josh Jennings Good morning. We are moving down the medical device track even further on Day Two of the TD Cowen 45th Annual Healthcare Conference.
Johnson & Johnson Just Paid Investors: Here's How Much They Got
Johnson & Johnson (NYSE: JNJ) is rewarding its shareholders once again with a quarterly dividend of $1.24, payable on Tuesday, March 4.
Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today
Johnson & Johnson (JNJ) reachead $167.28 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
3 Top High-Yield Dividend Stocks I Plan to Buy in March for More Passive Income
Generating passive income is a core aspect of my financial strategy. My goal is to eventually produce enough recurring investment income to cover my basic living expenses.
3 Dividend Stocks That Are No-Brainer Buys Right Now
It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Johnson & Johnson (JNJ) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
2 Very Healthy High-Yield Dividend Stocks to Buy for a Safe and Growing Passive Income Stream
A higher dividend yield is nice because it allows you to collect more dividend income on every dollar you invest in a stock. However, the company paying that dividend needs to be healthy to ensure it can maintain its payout during the tough times that inevitably come.
Johnson & Johnson (JNJ) Up 8.9% Since Last Earnings Report: Can It Continue?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.89, representing a +1.87% change from its previous close.
